Cite
Nshimyumukiza L, Duplantie J, Gagnon M, et al. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thromb J. 2013;11(1):14doi: 10.1186/1477-9560-11-14.
Nshimyumukiza, L., Duplantie, J., Gagnon, M., Douville, X., Fournier, D., Lindsay, C., Parent, M., Milot, A., Giguère, Y., Gagné, C., Rousseau, F., & Reinharz, D. (2013). Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thrombosis journal, 11(1), 14. https://doi.org/10.1186/1477-9560-11-14
Nshimyumukiza, Léon, et al. "Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model." Thrombosis journal vol. 11,1 (2013): 14. doi: https://doi.org/10.1186/1477-9560-11-14
Nshimyumukiza L, Duplantie J, Gagnon M, Douville X, Fournier D, Lindsay C, Parent M, Milot A, Giguère Y, Gagné C, Rousseau F, Reinharz D. Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model. Thromb J. 2013 Jul 17;11(1):14. doi: 10.1186/1477-9560-11-14. PMID: 23866305; PMCID: PMC3765702.
Copy
Download .nbib